Alirocumab: 13 agencies, 2015–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where alirocumab met resistance it was usually narrowed rather than refused: 12 of 27 decisive outcomes were recommendations with restrictions, against 7 outright refusals.
HAS (France) has been harder on alirocumab than on its own caseload: it refused 4 of 7 decisive submissions here (57%), against a base rate of 11% across everything it has assessed.
Assessment has run over 10.8 years, from 18 Aug 2015 at AWMSG (Wales) to 10 Jun 2026 at HAS (France).
PBAC (Australia) changed its position: not recommended in 2017, recommended by 2023, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for alirocumab.
Not every gap is a refusal: for alirocumab, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 10 of 37 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for alirocumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
6 of these 37 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess alirocumab, on 18 Aug 2015; CIPM (Spain) did not open a file until 19 Jun 2024 — an unusually long tail of 8.8 years between the earliest and latest system to look at it.
The record arrives in waves: 11 separate years each carry two or more decisions, spread across 12 years in total.
Restriction is doing real work here: 12 of 27 decisive outcomes narrowed alirocumab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), NICE (England) and PHARMAC (New Zealand) among others.
7 of the 13 agencies here assessed alirocumab more than once, HAS (France) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
alirocumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for alirocumab reads 12 restricted, 8 recommended, 7 not recommended and 4 no benefit, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 10 Jun 2026 | Listing (Transparency Committee) | ASMR V | source |
| AOTMIT (Poland) | 25 Jul 2025 | programu lekowego B.101. „Leczenie pacjentów z zaburzeniami lipidowymi (ICD-10: E78.01, I21, I22, I25) | not recommended | source |
| PBAC (Australia) | 2025 | Familial heterozygous hypercholesterolaemiaNon-familial hypercholesterolaemia | The PBAC rescinded the March 2023 recommendation for this drug. | source |
| TLV (Sweden) | 20 Sep 2024 | Praluent får utökad subvention | restricted subsidy | source |
| CIPM (Spain) | 19 Jun 2024 | Indicaciones terapéuticas autorizadas: Hipercolesterolemia primaria y dislipemia mixta Praluent está indicado en adultos… | financed by the SNS · art. 92 a, c | source |
32 further decisions for alirocumab, across 12 agencies, are not shown here. They include the most recent record on file, 10 Jun 2026 from HAS (France); its outcome is in the subscriber dataset. They link to 21 further source documents.
Related molecules
- evolocumab — divergent outcome (restricted vs recommended) on a shared indication
- bempedoic acid — divergent outcome (restricted vs not recommended) on a shared indication
- inclisiran — divergent outcome (restricted vs recommended) on a shared indication
- rosuvastatin — same ATC class C10A — Lipid modifying agents
- evinacumab — same ATC class C10A — Lipid modifying agents
- ezetimibe — same ATC class C10A — Lipid modifying agents
Coverage: 37 decisions for alirocumab from 13 agencies, 2015 to 2026. Data to 7 Sep 2026. ATC class C10A — Lipid modifying agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.